Price targets for Edwards Lifesciences are clustering in the mid to high US$90s and above US$100, while one model holds fair ...
Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled ...
Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...
Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...
Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Edwards LifesciencesEW stock reversed lower Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026. The medtech company makes nonsurgical replacements for faulty aortic, ...
Zacks Investment Research on MSN
Edwards Lifesciences stock up 22.1% in a year: What's driving it?
Edwards Lifesciences EW has delivered an impressive return over the past year, with shares rallying 22.1%. The stock comfortably outpaced the industry’s 3.8% fall and closely tracked the S&P 500 ...
Leerink Global Healthcare Conference 2026 March 11, 2026 10:00 AM EDTCompany ParticipantsScott Ullem - Corporate ...
Matthew Miksic Barclays Bank PLC, Research Division. All right. Thanks, everybody, for joining us this morning. Very pleased to have with us at our conference, Scott Ullem from Ed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results